Davis Polk advised the representatives of the several underwriters in the offering.Recursion Pharmaceuticals, Inc. executed its $500 million initial public offering of 27,878,787 shares of Class A…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Martina Bellini
…
This content is for Standard 1 Year members only. LoginJoin Now